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Abstract
Background: Despite our growing knowledge about the pathomechanisms of cancer cachexia, a whole clinical
picture of the cachectic patient is still missing. Our objective was to evaluate the clinical characteristics in cancer
patients with and without cachexia to get the whole picture of a cachectic patient.
Methods: Cancer patients of the University Clinic “Klinikum rechts der Isar” with gastrointestinal, gynecological,
hematopoietic, lung and some other tumors were offered the possibility to take part in the treatment concept
including a nutrition intervention and an individual training program according to their capability. We now report
on the first 503 patients at the time of inclusion in the program between March 2011 and October 2015. We
described clinical characteristics such as physical activity, quality of life, clinical dates and food intake.
Results: Of 503 patients with cancer, 131 patients (26.0%) were identified as cachectic, 369 (73.4%) as non-cachectic.
The change in cachexia were 23% reduced capacity performance (108 Watt for non-cachectic-patients and 83 Watt for
cachectic patients) and 12% reduced relative performance (1.53 Watt/kg for non-cachectic and 1.34 Watt/kg for
cachectic patients) in ergometry test. 75.6% of non-cachectic and 54.3% of cachectic patients still received curative
treatment.
Conclusion: Cancer cachectic patients have multiple symptoms such as anemia, impaired kidney function and
impaired liver function with elements of mild cholestasis, lower performance and a poorer quality of life in the EORTC
questionnaire. Our study reveals biochemical and clinical specific features of cancer cachectic patients.
Keywords: Cancer cachexia, Clinical parameters, Clinical picture
Background
Ongoing cachexia represents a significant factor affect-
ing the quality of life and prognosis of cancer patients.
Cachexia is present in up to 40% in early stages of patients
with gastrointestinal cancers and may be involved in up to
80% cancer deaths. However, it is still difficult to identify
cachectic patients, as 40–60% of cancer patients are over-
weight or obese, even in advanced cancer [1].
But what do we know about clinical features of cach-
exia patient?
Cachectic patients usually but not always demonstrate
lower body mass index (BMI), which is associated with an
increased risk of tumor progression [2, 3]. At the same
time, other groups report that BMI is not a prognostic
factor for cancer cachexia in a cohort of patients with 17%
obese, 35% overweight, 36% normal weight, and 12%
underweight persons [4]. Cancer cachectic patients experi-
ence numerous complications including reduced effective-
ness of chemotherapy [5, 6], reduced mobility, and
reduced functionality of muscle-dependent systems, such
as the respiratory and cardiovascular systems, leading to
decreased quality of life and survival [7–9]. Especially in
older population, cancer cachexia clinical features are key
predictors of one-year mortality [10]. There is a strong
correlation between decreased quality of life scores and
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decreased physical activity, which is strongly related to
weight loss [11]. It was demonstrated that cachectic pa-
tients present lower protein, albumins, and hemoglobin
levels [12].
Notably, cachexia is not an incurable situation. The
important message is that weight-losing patients with
unresectable pancreatic cancer can attenuate their weight
loss after eight weeks of intensive nutrition intervention,
and weight stabilization is associated with prolonged sur-
vival and improved quality of life [13]. However, despite
our growing knowledge about the pathomechanisms of
this symptom complex, a whole picture of the cachectic
patient is still missing.
Some studies aim to define diagnostic criteria of cancer
cachexia [14]. Usually, diagnostic tools for cachexia in-
clude loss of weight and lean body mass, fatigue, anorexia,
reduced physical performance (for example, total activity
or 6-min walk distance) and biochemical abnormalities of
c-reactive protein (CRP), albumin, and protein.
The existing concepts for the therapy of cachexia are
focusing either on nutrition or physical activity. There-
fore we founded a nutrition and exercise center for can-
cer patients in which we are focusing on the definition
of the cachectic patient and combined treatment of can-
cer cachexia with numerous therapy options. Our aim
was to evaluate the clinical characteristics such as phys-
ical activity, quality of life, clinical dates and food intake
in patients with and without cachexia to get the whole
picture of a cachectic patient.
Patients
From March 2011 cancer patients of the University Clinic,
“Klinikum rechts der Isar” with gastrointestinal (GI),
gynecological, hematopoietic, lung and some other tumors
were offered the possibility to take part in the treatment
concept including a nutrition intervention and an individ-
ual training program according to their capability. We now
report on the first 503 patients at the time of inclusion in
the program. All parameters like physical capability, daily
calorie intake or selected lab values were documented in a
prospectively designed database.
The exact definition of cachexia is a debatable issue in
medical literature (reviewed in [15]). We used the defin-
ition of malnutrition proposed by ESPEN (the European
Society for Clinical Nutrition and Metabolism) Consen-
sus Statement using following criteria [16]:
Weight loss (unintentional) > 10% indefinite of time,
or >5% over the last three months combined with
either
– BMI <20 kg/m2 if <70 years of age, or <22 kg/m2
if > 70 years of age or
– FFMI (fat-free mass index) <15 and 17 kg/m2 in
women and men, respectively.
Our definition of cachexia was also according to
Fearon and co-workers [17] and is used by other re-
searchers [18]. Here, the patients are defined as having
cachexia, either when they show a weight loss of 5%
during the last six months, or a weight loss of 2–5% in
combination with a BMI < 20, or a weight loss of 2–5%,
together with the presence of sarcopenia. Sarcopenia
was defined according to a report of the European work-
ing group on sarcopenia in older people (EWGSOP)
using first criterion (low muscle mass) plus either sec-
ond criterion (low muscle strength) or third criterion
(low muscle performance) [19, 20].
Methods
Laboratory parameters
Blood tests (red blood cells and white blood cells counts,
platelets, hemoglobin concentrations), serum electrolytes,
serum creatinine, c-reactive protein (CRP), liver function
tests (aspartate aminotransferase, alanine aminotransfer-
ase, alkaline phosphatase, serum bilirubin, and cholin-
esterase), coagulation tests, and serum albumin levels are
routinely performed upon admission to the clinic.
Performance
Endurance capacity, maximal power output (POmax)
and peak oxygen uptake (VO2peak) were measured as
described [21] in a submaximal incremental exercise test
on a computer-controlled bicycle ergometer. A stepwise
incremental exercise protocol was applied starting at 25
or 50 watts with increments of 25 watts every three mi-
nutes until volitional exhaustion or medical reasons for
exercise termination were reached. The exercise was ter-
minated prematurely in the case of significant ECG ab-
normalities, severe dyspnea or excessive blood pressure
increase to more than 230 mmHg systolic and/or less
than 110 mmHg diastolic.
Lung function
Spirometry provided a measurement of the forced vital
capacity (FVC) and the forced expiratory volume at the
end of the first second of forced expiration (FEV1).
Quality of life and mental health
Health-related quality of life (HRQoL) is important par-
ameter which can predict survival. It was assessed with
the 36-Item Short Form Health Survey SF-36 survey and
EORTC QLQ-C30. The EORTC QLQ-C30 is a HRQoL
measure specific to cancer, whereas the SF- is a generic
measure [22, 23]. The EORTC QLQ-C30 is a cancer-
specific measure that can capture patients’ functional
status in several domains (physical, psychological, and
social), their global health status/quality of life (QoL),
and symptom severity [22, 23].
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Mental health
The Hospital Anxiety and Depression Scale (HADS) was
used for identifying distress. There are two subscales: de-
pression (HADS-D) and anxiety (HADS-A). The optimal
cut-off point is to be ⩾8 for the identification of suspi-
cious cases and ⩾11 for safe cases on both subscales,
with a sensitivity and specificity of 0.80 on an average
[24]. With a score of ⩾13, it is possible to detect 76% of
the cases among cancer patients with a specificity of
0.60, whereas 95% of the cases can be detected with a
score of ⩾6 (specificity 0.21) [24].
Nutritional risk screening (NRS)
A diet record was performed to register food intake
(number of meals, calories intake/day, number and kind
of additional nutrition) as described [25].
Role of the funding source
The study was in part supported by Nutricia.
Statistical analysis
Results are expressed as median values. Statistical analyses
were performed using the SPSS (version 23, SPSS Inc.,
Chicago) software package. Two-sided tests and a signifi-
cance level of 0.05 were used. Values were compared by
Mann–Whitney U test for independent samples.
Results
The parameters of the patients are noted in Table 1.
One hundred thirty-one patients (26.0%) were classified
as cachectic, 369 (73.4%) as non-cachectic (Fig. 1). In 3
patients (0.6%) this information was not available. As ex-
pected, cachectic patients showed pronounced weight-
loss and lower values for BMI, nutrition score and
Karnofsky-Index (Table 2). 54.3% of cachectic patients
still receive curative treatment (Fig. 2).
Laboratory variables
Anemia parameters
In our study hemoglobin, erythrocytes and hematocrit
were significantly (p < 0.001) lower in cachectic patients
(Table 3). Excluding patients who received chemother-
apy at the time of evaluation or prior evaluation, the sig-
nificant difference (p = 0.015) in hemoglobin level is still
present (13.2 ± 1.3 g/dl for non-cachectic patients and
12.5 ± 1.5 g/dl for cachectic patients).
Serum albumin und protein values
Serum albumin and serum protein were significantly
decreased (p < 0.001) in cancer patients with cachexia
(Table 3).




number % number %
GI tumors 73 49,7% 74 50,3%
Gynecological tumors 208 89,3% 25 10,7%
Hematopoetic tumors 39 84,8% 7 15,2%
Lung tumors 11 61,1% 7 38,9%
Urological tumors 20 83,3% 4 16,7%
others 18 56,3% 14 43,8%
Fig. 1 Distribution of cachectic and non-cachectic in study cohort




BMI [kg/m2] 24,6 20,9 <0.001
Nutritional Risk Score 1 3 <0.001
FEV1 [l] 2,80 2,76 0.616
vital capacity [l] 3,5 3,4 0.688
IST capacity [%] 106 96 <0.001
ergometry [Watt] 108 83 <0.001
rel. performance [W/kg KG] 1,53 1,34 0.008
maximal heart frequency [/min] 153,0 145,5 0.070
Karnofsky-Index [%] 9 8 <0.001
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Kidney function
Both, median (0.8 mg/dl for non-cachexia and 0.8 mg/dl
for cachexia, Table 3) and mean (0.85 ± 0.24 mg/dl for
non-cachexia and 0.79 ± 0.19 mg/dl for cachexia) serum
creatinin values were significantly lower in cachexia
group (p = 0.042 for medians and p = 0.009 for means).
Urinary creatinine, as well as urinary values for IgG,
alpha-1-microglobulin and protein were significantly
higher in cachectic patients (Table 4).
Liver function and parameters of protein synthesis
Two cholestasis enzymes, alkaline phosphatase (ALP) and
gamma glutamyl transpeptidase (GGT), were significantly
increased in cancer patients with cachexia (Table 3). The
parameters of hepatocyte integrity, aspartate aminotrans-
ferase (AST) and alanine aminotransferase (ALT), were
not changed. Markers of liver synthesis function cholin-
esterase (CHE), serum albumin and serum protein, were
significantly decreased (p < 0.001). Totally, 187 patients
Fig. 2 Possibility of curative treatment in cachectic patients
Table 3 Selected laboratory blood parameters of cancer patients in the analysis of cachexia
Cachexia Cachexia
no yes p no yes p
median median median median
Sodium [mmol/l] 141 140 0.007 Calcium [mmol/l] 2,39 2,33 <0.001
Kalium [mmol/l] 4,4 4,4 0,237 Albumin [g/dl] 4,50 4,30 <0.001
Creatinine [mg/dl] ,8 ,8 0,042 CRP [mg/dl] ,1 ,2 0.019
Urea [mg/dl] 14 15 0,217 Triglycerides [mg/dl] 113 108 0.215
AP [U/l] 70 87 <0.001 Glucose [mg/dl] 93 94 0.452
Bilirubin [mg/dl] ,4 ,4 0,242 Quick [%] 100 98 0.167
GGT [U/l] 23 35 <0.001 Leukocytes [G/l] 5,39 6,03 0.054
GPT (ALAT) 25 26 0.670 Erythrocytes [T/l] 4,3 4,0 <0.001
GOT (ASAT) 27 29 0.753 Hemoglobin [g/dl] 13,1 12,0 <0.001
Cholinesterase [U/l] 7792 6703 <0.001 Hematocrit [%] 38,5 35,8 <0.001
LDH [U/l] 219 208 0.118 Thrombocytes [G/l] 232 243 0.150
Protein [g/dl] 7,0 6,8 <0.001
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(37% of all study participants) received chemotherapy at
the moment of inclusion in this study, 63 (33.7%) in cach-
exia group (this information was not available in 2 of pa-
tients) and 124 (66.3%) patients in non-cachexia group (this
information was not available in 4 patients). A significant
correlation was seen between AP and current chemother-
apy (r= 0.258, P < 0.001), GGT and current chemotherapy
(r= 0.205, P < 0.001), as well as CHE and current chemo-
therapy (r= − 0.182, P < 0.001). 66 (50.4%) cachexia and
245 (66.4%) non-cachectic patients did not receive chemo-
therapy at the moment of inclusion in this study. In
this group there is still a significant difference between
cachexia and non-cachexia regarding AP (p < 0.001),
CHE (p < 0.001), Quick (p < 0.05) and serum albumin
(p < 0.001) but not in case of GGT (p = 0.154).
Physical performance and lung function
Three parameters of endurance capacity (absolute and
relative performance) were significantly lower in cachec-
tic patients (Table 2).
The FEV1 and VC were not significantly decreased
(p = 0.616 and p = 0.688 respectively), and relative VC
was significantly lower in cachectic patients (Table 2).
Quality of life, mental health and food intake
There are significant differences between cachectic, and
non-cachectic patients regarding Global Health Score,
Physical Functioning Score, Role functioning score, Social
functioning score, Fatigue score, Nausea & vomiting score,
Appetite loss score and Diarrhoea score (p < 0.001).
Food intake
Cachectic patients understand the problem of weight
loss and take more meals per day as patients without
cachexia (Table 5). Cancer patients with cachexia some-
times receive more calories compared to cancer patients
without cachexia (Table 6). 12.5% of cachectic patients
receive already parenteral nutrition.
A summary of the clinical parameters of the cachectic
cancer patient is shown in Fig. 3.
Discussion
Our study demonstrated that cancer cachectic patients
have multiple symptoms such as anemia, impaired kid-
ney function and impaired liver function along with ele-
ments of mild cholestasis. Cachexia patients have low
level of protein and albumin. As a result significantly
more extracellular water and less intracellular water,
compared to patients without cachexia. This means that
not only low calories but also low oncotic pressure be-
cause of low protein play an important role in weight
loss in cachectic patients. In parallel to protein defi-
ciency, cachectic patients have lower performance pa-
rameters. The low levels of serum albumin, hematocrit,
and fibrinogen are well-known for cachectic patients but
probably not specific. Furthermore, the performance sta-
tus of cachectic patients – measured by ergometry - was
significantly reduced, leading to a poorer quality of life
in the EORTC questionnaire (Fig. 3).
Fearon and co-workers described a population consist-
ing of 170 advanced pancreatic cancer cachectic patients
using Karnofsky Performance Score, grip strength, diet-
ary intake, quality-of-life assessment with EuroQol EQ-
5D and QLQ-C30, CRP, and CA19-9, but they were
mostly concentrated on evaluation whether a 3-factor
profile incorporating weight loss, low food intake, and
systemic inflammation might relate better to a patient’s
overall prognosis than will weight loss alone [14].
Wallengren and co-workers report on 405 patients about
cachexia criteria like body mass index (BMI), weight loss,
fatigue, Karnofsky performance score, physical function
measured on a treadmill, low handgrip strength, lean tis-
sue depletion (DXA or arm muscle circumference), quality
of life measured by QLQ-C30 and abnormal biochemistry
(inflammation, anemia, or low serum albumin) [26]. The
biggest data set with 8160 patients was reported by Martin
and co-workers [3], but the authors were mainly focused
on BMI and % weight loss about overall survival to de-
velop a grading system. Takayama and co-workers ana-
lyzed 406 stage IV NSCLC patients using handgrip
strength, quality of life, Karnofsky Performance Scale, bio-
chemical parameters (white blood cell count, hemoglobin,
protein, albumin, triglycerides, calcium, CRP, and Insulin-
like growth factor-1) and survival [27]. In the study of
Theresen and co-workers 77 patients with advanced colo-
rectal carcinoma were described using clinical parameters
such as energy intake, the skeletal muscle mass cross-
sectional area, a tool for assessing nutritional status the




In our study population, the median hemoglobin was
12 g/dl and mean hemoglobin was 11.8 ± 1.5 g/dl. Our





Urinary creatinine [mg/dl] 102 169 0.001
Urinary albumin [mg/g crea] 9,9 9,9 0.053
Urinary protein [mg/g crea] 77 82 0,025
Urinary alpha-1-microglobulin [mg/g crea] 10 10 0.002
Urinary ß-NAG (U/g crea) [U/l] 5 5 0.003
Urinary IgG [mg/l] 4,3 6 <0.001
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data regarding anemia in cachectic patients are by other
groups. It was additionally reported using univariate Cox
proportional hazard regression that hemoglobin was sig-
nificantly associated with mortality risk [28]. According
to CACHEXIA score of Argiles and co-workers [29], a
tool for staging cachectic patients, hemoglobin in cach-
ectic patients should be below 12 g/dl.
Serum albumin und protein values
Although we observed hypoalbuminemia and hypopro-
teinemia in cachectic patients, these changes were not
severe. Additionally, we observed that calcium level in
cachectic patients was lower than in non-cachectic patients.
Taking into consideration that half of circulating calcium
ions are bound to albumin, this effect resulted probably
from hypoalbuminemia. Reasons for hypoalbuminemia are
usually decreased synthesis, increased degradation, or an
increased transcapillary escape rate [30]. We hypothesize
that the primary mechanism was decreased synthesis what
is supported through decreased liver synthesis function
measured using liver cholinesterase (Table 3). At the same
time decreased degradation was not observed because urin-
ary albumin was unchanged (Table 4).
According to Consensus Statement of the European So-
ciety of Clinical Nutrition and Metabolism (ESPEN), vis-
ceral proteins like serum albumin concentrations that are
good indicators of disease severity and outcome should
not be used for either screening or diagnosis of malnutri-
tion because of a low grade of nutrition specificity [16].
Kidney function
In our study there was a significant difference in serum
creatinine in cachectic and non-cachectic groups that is
by data of another working group [31], demonstrating that
serum creatinine can be a biomarker of skeletal muscle
mass in chronic kidney disease. The urinary excretion of
enzymes, in particular, N-acetyl-beta-D-glucosaminidase
(NAG) and alpha-1-microglobulin, non-invasive parame-
ters of the renal tubular function, were significantly higher
in cachectic patients.
Impaired liver function in cachexia
Two cholestasis markers, AP and GGT, were raised in
cachectic patients in isolation with normal bilirubin.
Though non-liver causes of this elevation like bone me-
tastases, hyperparathyroidism, renal impairment and
Paget’s disease are possible, the combination of two
markers makes liver problems more likely. One possible
explanation is the hepatotoxic effect of the chemother-
apy confirmed by the correlation between AP, GGT,
CHE and chemotherapy at the time of inclusion. The dif-
ference in AP, GGT, CHE between chemotherapy patients
and chemotherapy-naive patients were not significant in
our study. To our knowledge, elevated cholestasis markers
and decreased liver synthesis parameters were not de-
scribed in cancer cachexia until now. This elevation was
mild but present in cachexia in patients under chemother-
apy and without chemotherapy. Only for cardiac cachexia,
it was demonstrated that 60% of cachectic patients present
with abnormal cholestatic parameters [32]. Some authors
proposed the importance of the role of liver enzymes in
cancer cachexia (reviewed in [33, 34]) when a flow of
amino acids from skeletal muscle to the liver occurs and
serves for gluconeogenesis and acute-phase protein syn-
thesis. It was suggested that an interaction between the
tumor, peripheral blood mononuclear cells, and the liver
Table 5 The number of meals in cancer patients
Cachexia
no yes
number % number %
Calories intake/day <500 kcal/d 1 0,3% 0 0,0%
500 – 1000 kcal/d 6 1,8% 9 8,0%
1000 – 1500 kcal/d 54 16,3% 21 18,8%
1500 – 2000 kcal/d 203 61,1% 55 49,1%
2000 – 2500 kcal/d 64 19,3% 23 20,5%
>2500 kcal/d 4 1,2% 4 3,6%
Number of meals/day <3 21 6,0% 7 5,7%
3 – 5 290 82,6% 75 61,0%
>5 34 9,7% 37 30,1%
4 3 0,9% 0 0,0%
5 3 0,9% 4 3,3%
Additional nutrition no 348 96,1% 62 48,1%
yes 13 3,6% 63 48,8%
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may play a central role in the development and regulation
of cachexia [35]. The important role of the liver in cancer
cachexia was proposed by Lieffers and co-workers [36].
They hypothesized that a viscerally driven cachexia syn-
drome in patients with colorectal cancer originates from
an increase in mass of high-metabolic-rate tissues, such as
the liver and spleen.
Inflammation parameters (CRP) in cachexia
Increased CRP is supposed to be a valid laboratory and
clinical marker in cachexia [5, 14, 37, 38]. Fearon and
co-workers proposed that inclusion of a marker of sys-
temic inflammation (e.g., CRP) in a cachexia stratifica-
tion system could account for patients with real loss of
function also perceiving themselves to have reduced
function [14]. Though we saw a significant difference in
CRP-value between cachexia and non-cachectic patients.
This difference (0.1 mg/dl versus 0.2 mg/dl) is non-
specific to provide additional information to the clinician
when other accessible markers, such as serum hemoglobin
or cholinesterase are considered. In spite of some prog-
nostic scores for the assessment and treatment of cancer
cachexia, like the Glasgow Prognostic Score (GPS) [39] or
the cachexia score (CASCO) [29], which are based on
CRP and albumin values, we agree with Utech and co-
workers who suggest that inflammatory markers may not
necessarily improve our ability to predict survival when
cancer staging, serum albumin, and weight loss history are
available [28]. Additionally, we think that CRP is not ne-
cessarily a characteristic parameter in cancer cachexia be-
cause it is not routinely measured in clinical practice, in
Germany usually only if indicated.
Physical performance
Two parameters of endurance (capacity performance
and relative performance) were significantly lower in
cachectic patients. The dramatic change in cachexia was
23% reduced capacity performance (108 Watt for non-
Table 6 Quality of life and mental health
Cachexia
no yes
number median number median P
Global Health Score 329 58 116 50 <0.001
Physical Functioning Score 331 80 117 60 <0.001
Role functioning score 331 50 113 33 0.001
Emotional functioning score 327 58 114 58 0.739
Cognitive functioning score 338 83 116 83 0.976
Social functioning score 331 67 118 50 <0.001
Fatigue score 330 56 116 67 <0.001
Nausea & vomiting score 338 0 118 0 <0.001
Pain score 327 33 116 33 0.211
Dyspnoe score 339 33 118 33 0.908
Insomnia score 340 33 118 33 0.752
Appetite loss score 338 0 118 33 <0.001
Constipation Score 337 0 120 0 0.639
Diarrhoea score 338 0 120 0 <0.001
Financial difficulties score 337 0 116 0 0.407
Score HADS depression 336 5 118 6 0.172
Score HADS anxiety 339 7 116 6 0.104
SF36 role – physical 316 75 110 65 <0.001
SF36 physical role function 317 25 112 0 0.003
SF36 physical pain 324 62 114 57 0.572
SF36 general health 323 57 111 50 0.007
SF36 vitality 333 45 114 40 0.003
SF36 social function 332 69 118 50 0.002
SF36 role–emotional 313 67 111 67 0.397
SF36 physical well-being 327 64 111 60 0.377
Schwarz et al. BMC Cancer  (2017) 17:130 Page 7 of 10
cachectic-patients and 83 Watt for cachectic patients)
and 12% reduced relative performance (1.53 Watt/kg for
non-cachectic and 1.34 Watt/kg for cachectic patients)
in ergometry test.
Quality of life, mental health and food intake
Our results demonstrated that cachexia leads to a reduced
quality of life, but the mental health is still stable. The
mean value for global quality of life score was 55.7 ± 20.0
for non-cachectic patients and 47.7 ± 21.6 for cachectic
patients, which is worse than the EORTC reference
value global score of 61.3 ± 24.2 for all cancer types,
and worse than values in other studies (for example,
68.73 ± 19.05 for patients with different cancer types
on chemotherapy [40]).
These data are of special importance because for
the EORTC QLQ-C30, both the general health and
functioning scales and symptom scales (Dyspnea and
Appetite Loss), as well as for the SF-36, role – emo-
tional, general health, energy/vitality, and social func-
tioning significantly predicted survival [23].
Fearon and co-workers report that weight loss alone
(≥10%) did not define a population that differed from
self-reported functional aspects of quality of life [14]. With
our present study, we were able to demonstrate slight but
significant changes in quality of life in cachectic patients
without using CRP as a diagnostic parameter for cachexia.
This could be explained by the different patient popula-
tions (pancreatic cancer patients that were not considered
suitable to receive systemic chemotherapy in the study of
Fearon and co-workers, and patients with mixed cancers
in our population).
Food intake
It is supposed that a reduction in food intake is common
in patients with progressive cancer and cachexia. Dys-
phagia, nausea, xerostomia and changes in taste and
smell may lead to diminished food intake and thereby
insufficient energy intake (reviewed in [1]). Our data
show that weight loss didn’t depend on calories because
cachectic patients know their problem and eat appropri-
ately after a medical recommendation. Additionally,
doctors recognize the problem of under-nutrition and
prescribe parenteral nutrition (in 12.3% of patients in
our cohort of cachectic patients). Tsoli and colleagues
confirm our result in murine model and report that not
only reduced food intake but dysregulated expression of
transcription factors that control lipid metabolism and
thermogenesis in brown adipose tissue lead to weight
loss during the development of cachexia [41]. So, despite
the same amount of meals per day, patients with cach-
exia had a reduced calorie intake.
Limitations
One potential limitation of this study was the observa-
tional design, so there may be bias inherent in who ul-
timately was referred to our nutrition-exercise center or
decided to participate in the study. Totally, 187 (37%) pa-
tients received chemotherapy at the moment of inclusion
in this study. This fact could influence the characteristics
of patients. The patients are inhomogeneous regarding the
Fig. 3 Schematic clinical picture of the cachectic patient
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type of cancer. However, future studies should be done in
more homogenous cancers patient populations.
Conclusion
Our study reveals biochemical and clinical specific
features of cancer cachectic patients. The positive fea-
ture of our study is that it was conducted on large
study groups (369 patients without cachexia and 131
patients with cachexia).
We were able to demonstrate that the problem of
cachectic patients is not the calorie intake but protein
turnover and maybe disorder in fat metabolism. There-
fore we postulate that cachectic patients should be
treated as high-risk patients and propose that after diag-
nosis of cachexia the patients should be presented to a
cachexia team including “leading doctor” (for, example a
surgeon, oncologist or internist, who supervises the treat-
ment), nutritional specialist, clinical pharmacist, sports
scientist and psychiatrist.
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